AORT · Artivion, Inc.
$27.55
+0.54 (+2.00%)
At close · Jul 29
Market Cap
$1.31B
Shares
48.54M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| J. Patrick Mackin | CEO | $6,883,108 |
| Lance Berry | CFO | $2,977,091 |
| John E. Davis | Senior Vice President, Chief Commercial Officer | $1,958,047 |
| Jean F. Holloway | General Counsel | $1,909,597 |
| Marshall S. Stanton | Senior Vice President, Clinical Research and Chief Medical Officer | $1,660,393 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| J. Patrick Mackin | CEO | $5,511,940 |
| Lance Berry | CFO | $2,574,033 |
| Jean F. Holloway | General Counsel | $1,515,413 |
| John E. Davis | Senior Vice President, Chief Commercial Officer | $1,491,482 |
| Marshall S. Stanton | Senior Vice President, Clinical Research and Chief Medical Officer | $1,293,613 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| J. Patrick Mackin | CEO | $3,176,413 |
| Lance Berry | CFO | $1,638,357 |
| Lance A | CFO | $1,638,357 |
| D. Ashley Lee | CFO | $1,375,917 |
| Amy D. Horton | Chief Accounting Officer | $1,061,924 |
| Jean F. Holloway | General Counsel | $993,719 |
| John E. Davis | Senior Vice President, Chief Commercial Officer | $953,405 |
| Marshall S. Stanton | Senior Vice President, Clinical Research and Chief Medical Officer | $942,000 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| J. Patrick Mackin | CEO | $7,216,340 |
| D. Ashley Lee | CFO | $2,330,212 |
| Jean F. Holloway | General Counsel | $1,666,379 |
| John E. Davis | Senior Vice President, Chief Commercial Officer | $1,628,590 |
| Marshall S. Stanton | Senior Vice President, Clinical Research and Chief Medical Officer | $1,609,031 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| J. Patrick Mackin | CEO | $4,628,566 |
| Jean F. Holloway | General Counsel | $1,577,933 |
| D. Ashley Lee | CFO | $1,502,053 |
| John E. Davis | Senior Vice President, Chief Commercial Officer | $1,126,632 |
| Marshall S. Stanton | Senior Vice President, Clinical Research and Chief Medical Officer | $947,228 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| J. Patrick Mackin | CEO | $3,415,458 |
| D. Ashley Lee | CFO | $1,183,874 |
| Jean F. Holloway | General Counsel | $961,742 |
| John E. Davis | Senior Vice President, Chief Commercial Officer | $900,301 |
| Michael S. Simpson | Senior Vice President, Regulatory Affairs and Quality Assurance | $862,437 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| J. Patrick Mackin | CEO | $6,453,541 |
| D. Ashley Lee | CFO | $1,737,648 |
| Jean F. Holloway | General Counsel | $1,391,065 |
| Michael S. Simpson | Senior Vice President, Regulatory Affairs and Quality Assurance | $1,371,193 |
| John E. Davis | Senior Vice President, Chief Commercial Officer | $1,355,191 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| J. Patrick Mackin | CEO | $3,231,170 |
| D. Ashley Lee | CFO | $1,261,670 |
| Jean F. Holloway | General Counsel | $1,031,941 |
| John E. Davis | Senior Vice President, Chief Commercial Officer | $923,369 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| J. Patrick Mackin | CEO | $2,737,304 |
| D. Ashley Lee | CFO | $1,134,102 |
| Jean F. Holloway | General Counsel | $893,174 |
| John E. Davis | Senior Vice President, Chief Commercial Officer | $841,036 |
Key facts
CIK
784199
CUSIP
228903100
13F (30d)
38 filings
38 filers
Visit website
Investor relations